KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.96

Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.

Vincent Lévy, Tushar Srivastava, Raju Gautam, Shilpi Swami, Kaijun Wang, Keri Yang, Leyla Mohseninejad

Leuk Lymphoma 66(10) 1884-1892

PMID40407269
PMCID-
DOI10.1080/10428194.2025.2506501
发表日期2025-05-23
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

Zanubrutinib demonstrated significantly longer progression-free survival versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in the ALPINE trial. This post-hoc analysis using ALPINE data aimed to understand the benefit-risk associated with zanubrutinib versus ibrutinib employing quality-adjusted time without symptoms/toxicity (Q-TWiST) methodology. Survival data were partitioned into 3 health-states: TOX (time with toxicity); TWiST (time without symptoms/toxicity); and REL (time after relapse). Q-TWiST was estimated as mean time in each health-state weighted by respective utility score. In the base case, comprising high-risk patients, mean durations (in months) for zanubrutinib versus ibrutinib were 11.54 versus 11.38 (TOX), 14.45 versus 11.09 (TWiST), and 1.70 versus 3.78 (REL). Mean duration of Q-TWiST was 21.07 (zanubrutinib) versus 18.67 months (ibrutinib; difference: 2.40 months; 95%CI: 1.9-2.9; p<.001). This analysis demonstrated a significant Q-TWiST gain for zanubrutinib versus ibrutinib in high-risk R/R CLL patients, providing valuable insights that may inform clinical decision-making.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。